POTELIGEO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Japan, Lithuania, Poland, Romania, Spain, UK.

Active ingredients

The drug POTELIGEO contains one active pharmaceutical ingredient (API):

1	Mogamulizumab UNII YI437801BE - MOGAMULIZUMAB
	Mogamulizumab is a defucosylated, humanised IgG1 kappa immunoglobulin that selectively binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs including the skin, resulting in depletion of the target cells.
	Read more about Mogamulizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
POTELIGEO Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX09	Mogamulizumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1783638
ES	Centro de información online de medicamentos de la AEMPS	1181335001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	533964
FR	Base de données publique des médicaments	62292771
GB	Medicines & Healthcare Products Regulatory Agency	382328
IL	מִשְׂרַד הַבְּרִיאוּת	9342
IT	Agenzia del Farmaco	047420017
JP	医薬品医療機器総合機構	4291422A1021
LT	Valstybinė vaistų kontrolės tarnyba	1086750
PL	Rejestru Produktów Leczniczych	100416714
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67184001
US	FDA, National Drug Code	42747-761